Epigenetic Biomarker

A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.

Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.

Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.

Types of epigenetic biomarkers:

  • DNA methylation, circulating or noncirculating
  • MicroRNA and other noncoding RNA
  • Protein markers

For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.

    Related Conference of Epigenetic Biomarker

    March 18-19, 2024

    5th Global Summit on Oncology and Hematology

    Zurich, Switzerland
    June 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Barcelona, Spain
    July 11-12, 2024

    24th World Congress on Cancer and Diagnostics

    Vancouver, Canada
    July 18-19, 2024

    14th World Congress on Breast Cancer

    Paris, France
    September 19-20, 2024

    25th World Congress on Cancer Summit

    Paris, France

    Epigenetic Biomarker Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in